Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MCM3AP (ImmuneEditome ID:8888)

1. Gene summary of enriched editing regions for MCM3AP

Gene summary

Gene information	Gene symbol	MCM3AP
	Gene ID	8888
	GeneSynonyms	GANP\|MAP80\|PNRIID\|SAC3
	GeneCytomap	21q22.3
	GeneType	protein-coding
	GeneDescription	germinal-center associated nuclear protein\|80 kDa MCM3-associated protein\|MCM3 acetylating protein\|MCM3 acetyltransferase\|MCM3 import protein\|MCM3 minichromosome maintenance deficient 3 associated protein\|germinal center-associated nuclear protein\|germinal-centre associated nuclear protein
	GeneModificationdate	20230404
	UniprotID	O60318;A0A0A0MSZ7
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr21:46267765-46269407:-	ENST00000486937.4	ENSG00000160294.9	MCM3AP	ncRNA_exonic	AluSz,L2a,AluJb,AluJo,AluSx1	chr21:46267765-46269407:-.alignment
chr21:46270673-46271869:-	ENST00000479557.1	ENSG00000160294.9	MCM3AP	ncRNA_intronic	AluSx,FRAM,AluJb	chr21:46270673-46271869:-.alignment
chr21:46283055-46283211:-	ENST00000291688.4	ENSG00000160294.9	MCM3AP	intronic	AluSc8	chr21:46283055-46283211:-.alignment
chr21:46283055-46283211:-	ENST00000397708.1	ENSG00000160294.9	MCM3AP	intronic	AluSc8	chr21:46283055-46283211:-.alignment

Top

2. Tumor-specific enriched editing regions for MCM3AP

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr21:46267765-46269407:-	ESCA	Path	EER	1.1831e-02	8.5819e-03	0.2296
ENSG00000160294.9,MCM3AP	ESCA	Path	EAG	1.3800e-02	9.8549e-03	0.2248
chr21:46267765-46269407:-	LUAD	Path	EER	5.5726e-03	4.3385e-02	0.1966

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr21:46267765-46269407:-	BLCA	EER	3.6372e-02	2.7547e-03	2.4255e+03
ENSG00000160294.9,MCM3AP	GBM	EAG	1.7268e-04	1.7813e-02	1.3313e+01

Top

3. Enriched editing regions and immune related genes for MCM3AP

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for MCM3AP

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for MCM3AP

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr21:46267765-46269407:-	BRCA	EER	T_cells_CD4_memory_resting	2.0043e-02	-0.1333
chr21:46270673-46271869:-	BRCA	EER	NK_cells_activated	6.6288e-03	-0.3335
ENSG00000160294.9,MCM3AP	BRCA	EAG	T_cells_CD4_memory_resting	1.1814e-02	-0.1387
ENSG00000160294.9,MCM3AP	COAD	EAG	Dendritic_cells_activated	2.5134e-02	0.4301
chr21:46267765-46269407:-	ESCA	EER	NK_cells_resting	4.7602e-03	-0.2324
chr21:46270673-46271869:-	ESCA	EER	Macrophages_M0	3.7595e-04	0.5825
ENSG00000160294.9,MCM3AP	ESCA	EAG	T_cells_CD4_memory_activated	9.9621e-03	-0.2119
ENSG00000160294.9,MCM3AP	GBM	EAG	T_cells_CD4_memory_resting	2.5580e-02	-0.3009
chr21:46267765-46269407:-	KIRP	EER	T_cells_regulatory_(Tregs)	8.9903e-03	-0.4614
ENSG00000160294.9,MCM3AP	KIRP	EAG	T_cells_regulatory_(Tregs)	2.8108e-03	-0.5036
chr21:46267765-46269407:-	LGG	EER	Monocytes	1.4928e-03	0.2101
chr21:46270673-46271869:-	LGG	EER	Eosinophils	4.7403e-02	0.1679
ENSG00000160294.9,MCM3AP	LGG	EAG	T_cells_gamma_delta	2.7296e-03	0.1855
chr21:46267765-46269407:-	PRAD	EER	Mast_cells_activated	3.9314e-02	0.2418
ENSG00000160294.9,MCM3AP	PRAD	EAG	Mast_cells_activated	4.6987e-02	0.2271
chr21:46267765-46269407:-	STAD	EER	Macrophages_M1	8.7275e-03	0.1810
ENSG00000160294.9,MCM3AP	STAD	EAG	Macrophages_M1	4.7634e-03	0.1901
chr21:46267765-46269407:-	TGCT	EER	NK_cells_activated	1.2859e-02	0.3948
ENSG00000160294.9,MCM3AP	TGCT	EAG	NK_cells_activated	4.3967e-03	0.4358

Top

6. Enriched editing regions and immune gene sets for MCM3AP

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr21:46270673-46271869:-	BRCA	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EER	6.7272e-03	0.3330
ENSG00000160294.9,MCM3AP	BRCA	GSVA_HALLMARK_HYPOXIA	EAG	2.0872e-02	0.1273
chr21:46267765-46269407:-	ESCA	GSVA_HALLMARK_MYOGENESIS	EER	2.3390e-02	0.1876
ENSG00000160294.9,MCM3AP	ESCA	GSVA_HALLMARK_MYOGENESIS	EAG	1.5435e-02	0.1995
chr21:46270673-46271869:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	7.8227e-04	0.5559
ENSG00000160294.9,MCM3AP	GBM	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	1.0696e-02	0.3416
chr21:46267765-46269407:-	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.6271e-02	-0.2911
chr21:46270673-46271869:-	KIRC	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	7.8156e-04	0.6625
ENSG00000160294.9,MCM3AP	KIRC	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.9541e-02	0.2500
ENSG00000160294.9,MCM3AP	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	4.5371e-03	0.2321
chr21:46267765-46269407:-	LAML	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.8558e-03	0.2303
chr21:46270673-46271869:-	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	2.8375e-02	0.1853
chr21:46267765-46269407:-	LGG	GSVA_HALLMARK_NOTCH_SIGNALING	EER	2.6850e-03	0.1988
ENSG00000160294.9,MCM3AP	LGG	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	1.6384e-03	0.1947
chr21:46267765-46269407:-	LUAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.6621e-02	-0.2344
chr21:46267765-46269407:-	LUSC	GSVA_HALLMARK_COAGULATION	EER	3.6854e-02	0.2679
ENSG00000160294.9,MCM3AP	LUSC	GSVA_HALLMARK_COAGULATION	EAG	4.2529e-02	0.2585
chr21:46267765-46269407:-	OV	GSVA_HALLMARK_ADIPOGENESIS	EER	2.0258e-03	0.2634
ENSG00000160294.9,MCM3AP	OV	GSVA_HALLMARK_ADIPOGENESIS	EAG	2.4565e-03	0.2540
chr21:46267765-46269407:-	PRAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	7.6260e-03	0.3099
ENSG00000160294.9,MCM3AP	PRAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	9.6004e-03	0.2934
ENSG00000160294.9,MCM3AP	SARC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.2880e-02	-0.5454
chr21:46270673-46271869:-	STAD	GSVA_HALLMARK_P53_PATHWAY	EER	9.2936e-05	0.4332
chr21:46267765-46269407:-	STAD	GSVA_HALLMARK_GLYCOLYSIS	EER	1.1414e-04	0.2637
ENSG00000160294.9,MCM3AP	STAD	GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING	EAG	1.0804e-06	0.3225
chr21:46267765-46269407:-	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.9843e-02	0.3462
ENSG00000160294.9,MCM3AP	THCA	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	4.5495e-03	0.3804

Top

7. Enriched editing regions and drugs for MCM3AP

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr21:46267765-46269407:-	BLCA	AZD6244	EER	3.6826e-02	-0.3312
ENSG00000160294.9,MCM3AP	BLCA	AZD6244	EAG	2.4454e-02	-0.3314
chr21:46270673-46271869:-	BRCA	CCT018159	EER	2.8121e-03	-0.3648
chr21:46267765-46269407:-	BRCA	BMS.754807	EER	1.5679e-02	-0.1385
ENSG00000160294.9,MCM3AP	BRCA	Bexarotene	EAG	3.3226e-02	-0.1174
ENSG00000160294.9,MCM3AP	COAD	Bleomycin	EAG	2.3070e-02	0.4358
chr21:46267765-46269407:-	ESCA	GW.441756	EER	7.4239e-03	-0.2207
ENSG00000160294.9,MCM3AP	ESCA	GNF.2	EAG	5.0538e-03	-0.2301
chr21:46270673-46271869:-	ESCA	JNJ.26854165	EER	2.1907e-02	-0.4038
ENSG00000160294.9,MCM3AP	GBM	Embelin	EAG	6.2216e-03	0.3645
chr21:46267765-46269407:-	GBM	Embelin	EER	2.2965e-02	0.3149
chr21:46267765-46269407:-	KIRC	Gefitinib	EER	2.1517e-02	-0.2567
chr21:46270673-46271869:-	KIRC	CI.1040	EER	9.7366e-04	-0.6535
ENSG00000160294.9,MCM3AP	KIRP	Bexarotene	EAG	3.6173e-02	0.3660
chr21:46267765-46269407:-	LAML	CCT007093	EER	1.0206e-02	0.2106
ENSG00000160294.9,MCM3AP	LAML	CCT007093	EAG	8.0664e-03	0.2170
chr21:46270673-46271869:-	LGG	Etoposide	EER	3.1547e-02	0.1818
chr21:46267765-46269407:-	LGG	AS601245	EER	5.3439e-04	-0.2286
ENSG00000160294.9,MCM3AP	LGG	AS601245	EAG	1.7284e-04	-0.2313
chr21:46267765-46269407:-	LUAD	BIBW2992	EER	2.7887e-03	0.2904
ENSG00000160294.9,MCM3AP	LUAD	BIBW2992	EAG	7.5560e-03	0.2546
chr21:46267765-46269407:-	LUSC	JW.7.52.1	EER	2.0562e-02	-0.2960
ENSG00000160294.9,MCM3AP	LUSC	JW.7.52.1	EAG	2.3866e-02	-0.2867
chr21:46267765-46269407:-	OV	Methotrexate	EER	3.2410e-03	0.2516
ENSG00000160294.9,MCM3AP	OV	Methotrexate	EAG	1.4346e-03	0.2669
chr21:46267765-46269407:-	PRAD	Epothilone.B	EER	1.8734e-02	-0.2746
ENSG00000160294.9,MCM3AP	PRAD	Epothilone.B	EAG	3.8905e-02	-0.2359
ENSG00000160294.9,MCM3AP	SARC	Cisplatin	EAG	9.9483e-04	0.6790
chr21:46267765-46269407:-	SKCM	EHT.1864	EER	1.6542e-03	-0.3827
ENSG00000160294.9,MCM3AP	SKCM	EHT.1864	EAG	2.2206e-03	-0.3573
chr21:46267765-46269407:-	STAD	Gefitinib	EER	2.1194e-02	0.1593
chr21:46270673-46271869:-	STAD	MG.132	EER	7.4319e-03	-0.3048
ENSG00000160294.9,MCM3AP	STAD	Gefitinib	EAG	7.8892e-03	0.1795
chr21:46267765-46269407:-	TGCT	Metformin	EER	2.9247e-02	-0.3494
ENSG00000160294.9,MCM3AP	TGCT	Metformin	EAG	2.4432e-02	-0.3510
chr21:46267765-46269407:-	THCA	Methotrexate	EER	4.4579e-03	-0.4162
ENSG00000160294.9,MCM3AP	THCA	Methotrexate	EAG	3.0173e-03	-0.3962

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType